F063 HIV and STIs: Hot Topics
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
Sexually transmitted infection rates have been rapidly increasing in the post-pandemic world. Patients frequently present to their dermatologist for evaluation and management of their STIs. The nature of infectious diseases is that the epidemiology and treatment options are always changing. This session will update the clinicians with the latest trends in STIs like HIV, HPV, Mpox and syphilis and guide them in appropriate lab testing and best and newest treatment options for their patients.
LEARNING OBJECTIVES
Recognize the changing epidemiology of sexually transmitted infections that affect the skin.
Order appropriate lab evaluations for patients with STIs.
Select the most appropriate treatment for patients with STIs that affect the skin.
SCHEDULE
5:00 PM
Mpox and Emerging Infections
Kieron S. Leslie, MBBS
5:30 PM
Herpes Viruses Updates
John Christopher Trinidad, MD, MPH, FAAD
6:00 PM
HPV Updates
Joel Palefsky, MD
6:30 PM
Syphilis
Erin H. Amerson, MD, FAAD
SPEAKERS
Erin H. Amerson, MD, FAAD
Kieron S. Leslie, MBBS
Joel Palefsky, MD
John Christopher Trinidad, MD, MPH, FAAD
SPEAKER DISCLOSURES
Erin H. Amerson, MD, FAAD
No financial relationships exist with ineligible companies.
Kieron S. Leslie, MBBS
No financial relationships exist with ineligible companies.
Joel Palefsky, MD
Asieris Pharmaceuticals – Consultant (1099 relationship)(Honoraria); GlaxoSmithKline Immunology – Consultant (1099 relationship)(Honoraria); Merck & Co., Inc – Advisory Board(Honoraria); Roche Molecular Diagnostics – Consultant(Grants/Research Funding); Spotlight Therapeutics – Consultant (1099 relationship)(Honoraria); Vir Biotechnology – Consultant(Honoraria); Virion Therapeutics – Consultant(Stock Options);
John Christopher Trinidad, MD, MPH, FAAD
No financial relationships exist with ineligible companies.